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PTATE-OF-THE-ART PAPER
he Quantification of Infarct Size
aymond J. Gibbons, MD,* Uma S. Valeti, MD,* Philip A. Araoz, MD,† Allan S. Jaffe, MD*
ochester, Minnesota
We sought to summarize the published evidence regarding the measurement of infarct size
by serum markers, technetium-99m sestamibi single-photon emission computed tomography
(SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement
of infarct size is an attractive surrogate end point for the early assessment of new therapies for
acute myocardial infarction. For each of these three approaches, we reviewed reports
published in English providing the clinical validation for the measurement of infarct size and
the relevant clinical trial experience. The measurement of infarct size by serum markers has
multiple theoretical and practical limitations. The measurement of troponin is promising, but
the available data validating this marker are limited. Sestamibi SPECT imaging has five
separate lines of published evidence supporting its validity and has received extensive study in
multicenter trials. Magnetic resonance imaging has great promise but has less clinical
validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is
currently the best available technique for the quantitation of infarct size to assess the
incremental treatment benefit of new therapies in multicenter trials of acute myocardial
infarction. (J Am Coll Cardiol 2004;44:1533–42) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.06.071Cardiology Foundation
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eultiple end points have been used to assess the efficacy of
eperfusion therapy in dozens of randomized trials (1). The
easurement of infarct size has several advantages: 1) it
ermits early pilot studies to test the potential efficacy of
ew approaches, 2) it can serve as an end point for
ose-ranging studies to select the most appropriate dose of
new drug for larger studies, and 3) it can potentially
emonstrate the efficacy of a new therapy that is equivalent
o an existing therapy with respect to early mortality but
ay still have a favorable impact on long-term mortality.
This review will focus on three approaches that are
otentially available for the measurement of infarct size:
erum (biochemical) markers, technetium (Tc)-99m sesta-
ibi single-photon emission computed tomography
SPECT) myocardial perfusion imaging, and magnetic
esonance imaging (MRI). Although measurements of
lobal and regional left ventricular function often are used
linically in the estimation of infarct size, these measure-
ents are less direct and are influenced by the presence of
rrhythmias, cardiomyopathies, valvular heart disease, and
entricular loading (2). Electrocardiographic assessment of
nfarct size also is useful clinically; however, even when
arefully analyzed and expressed on an ordinal scale, it has
imited ability to resolve small differences in infarct size.
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ccepted June 14, 2004.ERUM (BIOCHEMICAL) MARKERS
athophysiologic principles. Once experimental data
onfirmed that the evolution of acute myocardial infarction
MI) was dynamic and could potentially be modified,
esearchers began to quantitate infarct size using biochem-
cal markers (3). The initial marker of interest was total
reatine kinase (CK) (3), which evolved to CK-MB fraction
CK-MB) when practical assays for the isoenzyme became
vailable (4). The critical parameters needed to estimate
nfarct size in this manner were defined in a series of
igorous experimental studies (5). These included: 1) The
uantity of CK that was released into the plasma compared
ith that depleted from the myocardium. This is known as
he release ratio. 2) The optimal sampling intervals to
rovide an accurate area under the time activity (or time
oncentration) curve so that the total amount released could
e determined. 3) Sufficient information on the clearance
nd compartmentalization of the marker so that one could
alculate the clearance rate. 4) The relationship between
nfarct size measured in this manner and pathologically and
lectrocardiographically determined infarct size, measures of
eft ventricular function, and arrhythmias.
In canine models without reperfusion, approximately 85%
f the CK found in the myocardium (dogs have very little
K-MB) is depleted in response to ischemic-induced myo-
ardial injury (4,5). Fifteen percent remains in the Z band.
he amount of enzyme depleted from the heart is propor-
ional to the size of the infarction. However, of the 85%
epleted, only 15% reaches the circulation in the absence of
oronary recanalization. The remainder is hydrolyzed either
ocally or in lymph (5). As long as a predictable relationship
xists between the amount of CK depleted and the amount
hat reaches the circulation, serial samples permit a math-
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Infarct Size October 19, 2004:1533–42matic model of the amount depleted and, therefore, an
stimate of infarct size. Such a model requires estimation of
oth the volume of distribution and the clearance of CK so
hat the model can be corrected to reflect the amount of CK
eleased. The use of serial values on the downslope of the
ime activity curves to calculate a specific clearance rate (kd)
s equivalent in most cases to using a mean clearance rate.
ith sufficient samples, there is an excellent correlation
etween enzymatic and pathologic infarct size in animals
4,5).
ffects of reperfusion. In the presence of coronary reper-
usion, enzyme kinetics are altered in several ways. The
mount of marker released into the plasma relative to the
mount depleted from the myocardium increases substan-
ially. In animals with reperfusion within 2 h after coronary
cclusion, the release ratio (the amount of enzyme that is in
he plasma compared with that depleted from myocardium)
oubles (6). The release ratio is likely a continuous function
epending upon the time from the onset of the coronary
cclusion to recanalization and the abruptness of the reper-
usion because the washout of marker is flow-dependent.
he ability to model this system becomes problematic once
ne recognizes the range of release ratios related to these
arameters. The kinetics of release are also altered with a
uch more rapid peak and consequently a much faster
ecline. Thus, comparisons between reperfused and non-
eperfused patients are problematic because a different
igure 1. Relationship between commutative release of hydroxybutyrate
ehydrogenase (HBDH) during the course of 120 h and ejection fraction
n 54 patients. Although there was a highly significant correlation, there is
onsiderable scatter in data with a wide range of enzyme release for ejection
raction between 50% and 55% and a wide range in ejection fraction for
Abbreviations and Acronyms
CK  creatine kinase
CK-MB creatine kinase-MB fraction
HBDH  hydroxybutyrate dehydrogenase
MI  myocardial infarction
MRI  magnetic resonance imaging
SPECT  single-photon emission computed tomography
Tc  technetiumumulative enzyme release of between 1,500 and 2,000. Reprinted, with
ermission, from Dissman et al. (17).
C
Rmount of enzyme per gram of myocardium destroyed is
eleased into the blood. Even within the reperfused group,
iven the known marked differences in the rapidity and
agnitude of reflow and therefore the release ratio as well as
he time of peak CK, CK-MB, or troponin, meaningful
omparisons between areas under the curve and infarct size
re difficult. The ability to determine peak values also is
ore difficult because the peak is much earlier and, there-
ore, much more easily missed. However, some groups have
ttempted, in a series of studies in animals, to account for all
f the markers that can be lost from myocardium with and
ithout reperfusion (7). This has been attempted for both
ydroxybutyrate dehydrogenase (HBDH; LDH1 and
igure 2. Association between single troponin T (TnT) measurement at
2 h and peak creatine kinase (CK) with estimated thallium infarct size in
on-reperfused (A) and reperfused (B) patients. Reprinted, with permis-
ion, from Licka et al. (23).
able 1. Clinical Correlates of Tc-99m Sestamibi Infarct Size
Parameter Reference Year n r p Value
F (26) 1989 16 0.82 0.0001
F (28) 1990 32 0.80 0.0001
-week EF (28) 1990 32 0.81 0.0001
-week EF (31) 1994 20 0.81 0.0001
-yr EF (27) 1991 20 0.76 0.0001
SV at 1 yr (RNA) (27) 1991 20 0.76 0.0001
SV at 1 yr (CT) (29) 1995 14 0.80 0.0001
WM (26) 1989 16 0.81 0.0001
WM (28) 1990 32 0.75 0.0001
WM at 6 weeks (28) 1990 32 081 0.0001
reatine phosphokinase (30) 1991 17 0.78 0.002
hallium-201 (31) 1994 20 0.73 0.0002T  computed tomography; EF  ejection fraction; ESV  end-systolic volume;
NA  radionuclide angiography; RWM  regional wall motion.
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October 19, 2004:1533–42 Infarct SizeDH2) and total CK. With corrections, it was suggested
hat one could account for nearly all the marker depleted
rom the myocardium. However, these results depend
eavily on an assumed disappearance rate derived from
ulticompartmental modeling and the corrections, which
re not accepted universally. In addition, there is a very large
mount of HBDH in red cells (8); hemorrhagic infarcts may
laborate more HBDH than bland infarcts. This is an even
reater problem if there is any hemolysis (9) or if there is
leeding during/after intervention with breakdown of red
ells.
linical studies: no reperfusion. In patients, in the ab-
ence of reperfusion, enzymatic estimates of infarct size
orrelate with the ejection fraction, hemodynamics, arrhyth-
ias, and prognosis (10,11). Hackel et al. (12) reported an
xcellent correlation (Spearman r  0.87) between the
nzymatic estimates based on CK-MB and pathologic
easurements. There was slight underestimation of infarct
ize using enzymatic measurements.
Peak CK-MB can be used as a substitute for the area
nder the curve if one has a sufficient number of samples to
etect true peak values. Smith et al. (13) found that the
egree of underestimation of infarct size ranged from 14%
o 47% when the data from the upslope of the CK-MB time
ctivity curves were missing. The correlations were good for
oth Q-wave and non–Q-wave MI when peak values were
scertained (13). However, without sufficient samples, the
ikelihood of missing the peak enzyme concentration is
igh. This is particularly true if the study group includes
oth ST-segment and non–ST-segment elevation MIs be-
ause the enzyme peaks occur earlier with non–Q-wave MI.
hus, it would be easy to miss the peak without multiple
amples (14). Peak values may permit gross classification of
atient risk but that is substantially different from quanti-
cation of the amount of myocardial damage to permit
ndividual or group comparisons. Total CK and CK-MB
nfarct sizing were used to evaluate many (pre-reperfusion)
nterventions that were thought to reduce infarct size. The
igure 3. Relationship between the perfusion defect measured by single-
hoton emission computed tomography and the amount of scarring
easured by pathology in human hearts explanted at the time of cardiac
ransplantation. Reprinted, with permission, from Medrano et al. (32).ffects often were modest (15). reperfusion. In the reperfusion era, the most extensive
ork has been done with lactic dehydrogenase isoen-
ymes 1 and 2 (known also as HBDH). The potential
roblems with that approach were discussed earlier.
hese problems are confounded if only peak values are
sed, although some have claimed that one properly
imed sample at 72 h is adequate (16). However, the
elease of HBDH can continue beyond 72 h, although
he error induced by the absence of later samples is
hought to be modest (17). It is often difficult to time the
nset of the infarction and thus obtain the requisite
ample at the proper time. In tightly controlled studies,
nfarct size calculated from HBDH release does correlate
ith ejection fraction in patients with first infarction
Fig. 1) (18).
These issues, especially those related to bleeding/hemolysis
nd release of red cell HBDH, may help explain some of the
eported results where infarct size was estimated by HBDH.
hen streptokinase was compared with acute percutaneous
ransluminal coronary angioplasty (19), there were significant
ifferences in ejection fraction between the treatment groups in
oth anterior MI and non-anterior MI. However, the differ-
nces in HBDH release between treatment groups were
odest in anterior MI and insignificant in inferior MI. There
as no association between HBDH and ejection fraction in
he group undergoing percutaneous transluminal coronary
ngioplasty. In a randomized trial evaluating eniporide, the
ilot phase showed a significant reduction in HBDH release
ith two different doses of the drug, which was not confirmed
n the larger definitive trial (20).
Will troponin measurements permit more accurate deter-
ination of infarct sizes? The kinetics and release ratio of
he troponins are not well defined. The depletion of
roponin T but not troponin I has been reported to correlate
ith pathologic infarct size in dogs (21). However, the
elease ratio is unclear and could be different for the
ytosolic and structural pools. Given its improved specific-
ty, troponin should be a more accurate way to assess infarct
ize. Ideally, one would like to measure all the troponin
igure 4. Six-month mortality in 1,122 patients in the Collaborative
rganization for RheothRX Evaluation (CORE) trial, according to the
ingle-photon emission computed tomography infarct size measured at
ischarge. The groupings of infarct size were chosen on the basis of
revious studies. LV  left ventricle. Modified from Burns et al. (39).eleased and then correct for clearance to determine release
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Infarct Size October 19, 2004:1533–42nd infarct size. Unfortunately, troponin values remain
levated for up to two weeks. Serial sampling for this time
s difficult if not impossible. Thus, experiments have been
erformed exploring values at fixed time points, recognizing
he potential timing difficulties. Seventy-two-hour troponin
measurements correlate best with scintigraphically deter-
ined infarct size in animals and patients (Fig. 2) (22,23).
owever, none of the patient studies has pathologic con-
rmation. In each of the studies, the correlation with and
ithout reperfusion has been superior for troponin rather
han for CK-MB. Most of these studies have been con-
ucted with troponin T. Thus, the applicability of these
ndings to troponin I is uncertain. Troponin I must be
alidated separately, both experimentally and clinically,
iven the heterogenicity among troponin assays and poten-
ially different clearance. Initial data are promising (24).
C-99M SESTAMIBI SPECT IMAGING
ultiple animal studies demonstrated the potential value of
c-99m sestamibi in the assessment of reperfusion therapy.
etailed reviews are available (25). The efficacy of reperfu-
ion therapy can be assessed either by using both the acute
nd final perfusion defect to measure myocardial salvage or
ore simply by using the final defect to measure infarct size.
he latter approach, which has been increasingly favored for
ogistical reasons, is summarized here.
linical validation of the measurement. Five separate
ines of clinical evidence have validated the use of
PECT sestamibi imaging for the measurement of in-
arct size:
. There is a close association between sestamibi infarct
size and measurements that have been traditionally used
to assess infarct size in clinical medicine, including
ejection fraction, end-systolic volume, regional wall
motion, enzyme release, and resting thallium-201 myo-
cardial perfusion imaging (Table 1) (26–31).
. There is a close association between fibrosis in human
hearts and infarct size assessed by sestamibi (32–34).
igure 5. Infarct size and myocardial salvage measured by single-photon
mission computed tomography sestamibi imaging in patients treated with
issue plasminogen activator (tPA) and patients treated with stenting and
glycoprotein IIb/IIIa inhibitor. The stent group had a smaller infarct size
nd greater myocardial salvage. LV  left ventricle. Based on data from
chomig et al. (40).The defect measured by ex vivo sestamibi imaging ofmyocardial slices from explanted human hearts at the
time of cardiac transplantation is closely associated with
the quantitation of fibrosis by pathology (Fig. 3). Two
subsequent studies (33,34) showed a similar close asso-
ciation between in vivo sestamibi defect size and the
amount of fibrosis on surgical myocardial biopsies.
. The magnitude of sestamibi uptake predicts the re-
sponse of myocardium with abnormal function to sub-
sequent revascularization in chronic coronary artery
disease, and the recovery of myocardium after reperfu-
sion therapy for acute MI. Sestamibi uptake correlates
closely with the uptake of thallium on a resting redis-
tribution scan (35) and predicts improvement in func-
tion after revascularization (33,35). The mismatch be-
tween infarct size and ventricular function after
reperfusion therapy in acute MI identified myocardial
stunning in both retrospective (28) and prospective (36)
studies.
. Sestamibi infarct size measured at discharge predicts
short-term patient mortality in both single-center (37)
and multicenter (38) studies. In the largest series of
1,181 patients (39), there was a significant linear asso-
ciation between infarct size and six-month mortality
(Fig. 4).
. Most importantly, two separate randomized trials
(40,41) have now shown a corresponding improvement
in clinical outcome in association with a therapy that
reduces infarct size. This is an important requirement
from a regulatory standpoint to make certain that a
“surrogate” end point does not show benefit when there
is in fact clinical harm. A randomized trial (40) showed
that the use of stenting and a glycoprotein IIb/IIIa
inhibitor was associated with smaller infarct size and a
lower incidence of death, reinfarction, or stroke com-
pared with therapy with tissue plasminogen activator
(Figs. 5 and 6). In a second randomized trial (41),
stenting and thrombolysis were both combined with
abciximab. Stenting was associated with a smaller in-
igure 6. Clinical outcome in patients from the same randomized trial
hown in Figure 5. The cumulative incidence of death, infarction, and
troke was significantly lower in the stent group compared with the tissue
lasminogen activator group. Reprinted, with permission, from Schomig et
l. (40).farct size and better outcomes.
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October 19, 2004:1533–42 Infarct Sizeuantitative approach. Sestamibi infarct size has been
uantitated using a standardized approach (26) based on
ardiac phantom studies (42).
omparability of data from multiple centers. The feasi-
ility of performing multicenter trials using SPECT sesta-
ibi imaging was first demonstrated using a phantom
xperiment (43). The measured “infarct” size closely corre-
ates with the actual defect size in the phantom with an
verage absolute error of 3% of the left ventricle (43). The
uantitation is insensitive to differences in camera, collima-
or, or imaging routine. More than 600 centers in 19
ountries on 6 continents have successfully completed this
able 2. Multicenter Trials in Acute Myocardial Infarction
sing Sestamibi as an End Point
Type of Trial Reference Patients
ingle-center trials
Mayo tPA/PTC (46) 98
Munich stenting/tPA (STOPAMI) (40) 123
Munich stenting/tPA (STOPAMI-2) (41) 141
Munich facilitated PCI (BRAVE) (58) 228
Florence rheolytic thrombectomy/PCI (59) 100
Total single-center patients 690
ulticenter PTCA trials
Poloxamer 188/PTCA (48) 127
CALYPSO—CY1503/PTCA — 149
ALIVE—adenosine/PTCA — 46
FESTIVAL-Hu23 F2G/PTCA (safety) (49) 58
ADMIRE—adenosine agonist/PTCA (50) 290
HALT MI-Hu23 F2G/PTCA (efficacy) (45) 397
COOL MI—hypothermia/PCI (51) 325
LOWTEMP—hypothermia/PCI (feasibility) (52) 18
ACE—abciximab/PCI (53) 228
EMERALD—distal protection/PCI (60) 427
Total PTCA patients 2,065
ulticenter thrombolysis trials
Poloxamer 188/thrombolysis (54) 100
CORE—poloxamer 188/thrombolysis (44) 1,167
AMISTAD—adenosine/thrombolysis (47) 214
LIMIT AMI—anti-CD-18/thrombolysis (55) 355
AMISTAD II—adenosine/thrombolysis (56) 266
RAPSODY—P selection blocker/thrombolysis (57) 544
Total thrombolysis patients 2,646
CI  percutaneous coronary intervention; PTCA  percutaneous transluminal
oronary angioplasty; tPA  tissue plasminogen activator.
able 3. Clinical Correlates of Infarct Size Demonstrated by
agnetic Resonance Imaging
Parameter Reference Year n R p Value
eak CK-MB (78) 2001 24 0.90 0.001
eak CK (77) 2001 32 (3 mo) 0.77 0.0001
eak CK (77) 2001 19 (14 mo) 0.92 0.0005
eak CK (79) 2003 24 0.68 0.001
roponin I (8–12 h) (80) 2003 19 0.81 0.0001
K (8–12 h) (80) 2003 19 0.78 0.0001
SVI (79) 2003 24 0.55 0.01
F (81) 2004 18 0.63 0.001
ET infarct size (82) 2002 31 0.81 0.0001
ET-FDG uptake (83) 2003 26 0.85 0.001
K  creatine kinase; CK-MB  creatine kinase-MB fraction; EF  ejectionm
raction; ESVI  end-systolic volume index; PET  positron emission tomography;
ET-FDG  18F-draxyglucose positron emission tomography.hantom validation to ensure useful data in multicenter
rials. In one large trial (44), 98% of 1,184 studies provided
nalyzable end point data.
andomized clinical trial experience. There is consider-
ble randomized clinical trial experience (40–41,44–60)
sing sestamibi infarct size as an end point (Table 2). Five
ingle-center trials and 16 multicenter-randomized trials
ave been completed using sestamibi infarct size as an end
oint in 5,401 patients. Multiple additional trials are
ngoing.
Most trials have performed sestamibi imaging at 120 to
16 h after reperfusion, which was the time interval used in
any of the validation studies. Imaging at 30 days has been
erformed in two recent trials (51,52) in an effort to detect
ater cellular recovery.
RI
he basics of the technique. Infarct imaging by MRI uses
elayed contrast-enhanced imaging. A paramagnetic con-
rast agent such as gadolinium is first injected intravenously
61). Infarcted myocardium appears hyperenhanced relative
o normal myocardium when imaged 5 to 30 min later
62–66). The hyperenhancement of infarcted myocardium
ppears to be related to altered myocardial kinetics of
adolinium, resulting in its accumulation and prolonged
resence in the infarct (67–69).
Early studies of this delayed hyperenhancement had
imitations. In some animal studies using older sequences,
here was an overestimation of infarct size (67,68,70–72),
uggesting that the enhanced area represented both revers-
ble and irreversible myocardial injury. In addition to tech-
ical limitations, these earlier studies frequently did not
ccount for the transmural extent of hyperenhancement
efore labeling a segment as infarcted or stunned. This may
ave led to the conflicting reports that hyperenhanced
yocardium was viable (73).
Technical advances (reviewed elsewhere) (74) have con-
ributed to the more accurate estimation of infarct size. The
emainder of this section is based primarily on modern
maging sequences.
alidation of infarct size measurement by MRI in animal
tudies. Several animal studies have validated the measure-
ent of infarct size by contrast-enhanced MRI. In a canine
odel of acute and chronic infarction (63), infarct size by ex
ivo contrast-enhanced MRI correlated closely (r  0.99)
ith triphenyltetrazolium chloride staining. Other studies
onfirmed these findings in both canine (64) and rabbit (75)
odels. In a canine model (76), the transmural extent of
yperenhancement 3 days after an acute infarct predicted
unctional improvement by 28 days.
linical validation of MRI measurements. Several differ-
nt lines of evidence provide clinical validation for the use of
RI using segmented inversion recovery for the measure-
ent of infarct size.
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Infarct Size October 19, 2004:1533–42. There is a close association between MRI infarct size
and measurements that have been used clinically to
assess infarct size, including ejection fraction, regional
wall motion enzyme release, and positron emission
tomography imaging (Table 3) (77–83).
. The MRI infarct size predicts recovery of function after
revascularization (81,84–86) and after MI (Table 4)
(78,87–89). The transmural extent of the infarct ap-
pears to delineate viable and nonviable myocardium and
the recovery of function after revascularization (Fig. 7).
The extent of transmural enhancement also predicts
recovery of function after MI (78,87).
. In one small study of 44 patients (90), MRI infarct size
was significantly associated with cardiovascular events
(Fig. 8).
uantitative approach. Infarct size volume by MRI gen-
rally is measured by computer-assisted planimetry of the
able 4. Magnetic Resonance Imaging for Prediction of Function
eperfusion of Acute MI
Year Reference n Sn Sp
hronic CAD
2000 (84) 12 98 76
2000 (85) 41
2003 (86) 10
2004 (81) 18
cute MI
2001 (78) 24
2002 (87) 20
2003 (88) 23 83 72
2003 (89) 30
AD  coronary artery disease; MI  myocardial infarction; NPV  negative pred
igure 7. Relationship between the transmural extent of hyperenhancemen
mproved function after revascularization in 804 dysfunctional segments in 41 pat
f hyperenhancement and the likelihood of improved function. Reprinted, withyperenhanced myocardium. The area of hyperenhanced
yocardium is traced in each slice and multiplied by the
lice thickness and the myocardial density of 1.05 g/ml to
btain the infarct mass. A second method to quantify infarct
ize determines the enhancement score (0 to 4) for each
egment, sums these scores over all segments, and then
ivides this sum by the maximal possible score (total
umber of segments  4).
omparability of images from multiple centers. There
re no published studies to date evaluating the capability
nd comparability of studies from multiple centers.
se of MRI in clinical trials. There has been very limited
xperience to date with the use of MRI for infarct sizing in
linical trials. An early observational study (91) reported
hat MRI infarct size eight days after infarction was signif-
cantly smaller in patients who received reperfusion therapy.
n a substudy of 40 patients in a randomized trial (92), MRI
howed a smaller infarct size with streptokinase compared
ecovery After Revascularization of Chronic CAD or
PV NPV MR Parameter
Lack of delayed enhancement
1 79 25% transmural enhancement—all segments
8 89 25% transmural enhancement—segments
with akinesis or dyskinesis
5 Thick metabolically viable segments
2 Lack of delayed hyperenhancement
5 72 25% transmural enhancement
3 75 Lack of delayed hyperenhancement
3 72 50% transmural hyperenhancement
5 59 25% transmural enhancement
value; PPV  positive predictive value; Sn  sensitivity; Sp  specificity.
agnetic resonance imaging before revascularization and the likelihood ofal R
P
7
8
8
9
7
7
8
7t by m
ients. There was a clear inverse relationship between the transmural extent
permission, from Kim et al. (85).
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October 19, 2004:1533–42 Infarct Sizeith placebo. Both of these studies used older imaging
equences. There are no published randomized trials using
he current inversion recovery fast gradient technique.
here are no published data regarding the correct timing of
RI images after reperfusion.
omparison of SPECT and MRI. The limited available
ata suggest that MRI can detect smaller infarctions than
PECT and is more reproducible. Wagner et al. (93) found
hat SPECT thallium and MRI were highly specific for
nfarction and had similar sensitivity for transmural infarc-
ion. However, 47% of the segments identified as having
ubendocardial infarction by MRI were not detected by
PECT. In a second study (94) comparing resting SPECT
igure 8. Survival free of reinfarction, congestive heart failure, stroke, or
nstable angina requiring hospitalization for 43 patients grouped by infarct
ize obtained by magnetic resonance imaging. There was a significant
ssociation of infarct size with subsequent outcome. However, if unstable
ngina was removed from the definition of events, the relationship was no
onger significant. Reprinted, with permission, from Wu et al. (90).
Table 5. Comparison of SPECT and MRI for
Technical
Requires regular rhythm No
Resolution Low
Detection of infarction Tra
Reproducibility Mo
Variability We
Clinical validation
Association with other
parameters
Ext
Association with human
myocardial fibrosis
Thr
Recovery of function with 7 st
revascularization after acute
myocardial infarction
4 st
Association with patient outcome 3 st
m
Similar infarct size/outcome in
randomized group
2 st
Standardized quantitation Yes
Multicenter/comparability Yes
Randomized trial experience 21
*Excludes studies with semiquantitative segmental scores. †C
unstable angina.
MRI  magnetic resonance imaging; SPECT  single-photonhallium to MRI, MRI was superior in predicting myocar-
ial viability.
A single study (66) compared the reproducibility of
nfarct size determination by SPECT sestamibi and MRI
nd found that MRI infarct size was more reproducible.
he authors concluded that the numbers of patients needed
or clinical trials using MRI would be much smaller.
owever, this would be true only if paired imaging was
erformed to detect a change in infarct size over the course
f time. As reported by the authors, the standard deviation
f infarct size in their population of 15 patients was 6% for
RI and 7% for SPECT. These standard deviations would
ead to very similar sample size estimates for single (un-
aired) images comparing different treatments. Table 5
ummarizes the comparison of SPECT and MRI.
HE FUTURE CHALLENGE
uring the past decade, multiple randomized trials have
tudied an array of adjuvant therapies used with reperfusion
n acute MI. The results have been generally negative.
owever, there have been exceptions; in three separate
andomized trials using poloxamer 188 (54) and adenosine
47,56), SPECT sestamibi has shown treatment efficacy in
elatively modest numbers of patients.
The challenge of demonstrating incremental treatment
enefit with reperfusion therapy in acute MI is usually
nderestimated. The variability in infarct size in patients is
ubstantial, reflecting the known variability in the important
arameters of myocardium at risk, residual flow to the
nfarct zone (via collaterals or intermittent antegrade flow),
rct Sizing
PECT MRI
Yes
High
ral Transmural and
nontransmural
e High
blished Limited data
Extensive
dies None
, 261 patients 4 studies, 81 patients
, 191 patients 4 studies, 97 patients
,* 1633 patients,
ity
1 study, 44 patients,
combined events†
None
No
No
5,401 patients One trial, 40 patients,
old sequences
death, myocardial infarction, stroke, congestive heart failure,Infa
S
nsmu
derat
ll esta
ensive
ee stu
udies
udies
udies
ortal
udies
trials,
ardiacemission computed tomography.
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Infarct Size October 19, 2004:1533–42nd time to reperfusion (95). Current reperfusion therapy is
ighly effective. Nearly 50% of patients will have infarcts of
10% of the left ventricle with current therapy (37). The
ncremental benefit of ancillary therapy will be small in these
atients. Sizable treatment benefit will be restricted to the
0% of patients with infarcts of 10% of the left ventricle.
he overall incremental benefit of ancillary therapy, there-
ore, will be modest and difficult to measure against the
ackground of the tremendous variability in infarct size.
he measurement of troponin is promising, but the avail-
ble data validating this marker are limited. Magnetic
esonance imaging has definite technical advantages and
reat promise, but there are as yet no multicenter trial data
o confirm this. On the basis of existing evidence, SPECT
estamibi imaging currently is the best technique available
o meet this challenge.
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